このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Hisamitsu Pharmaceutical マネジメント

マネジメント基準チェック /24

Hisamitsu Pharmaceutical'sの CEO はKazuhide Nakatomiで、 May2015年に任命され、の在任期間は 9.08年です。は、会社の株式の0.33%を直接所有しており、その価値は¥ 922.19M 。経営陣と取締役会の平均在任期間はそれぞれ6.1年と10.1年です。

主要情報

Kazuhide Nakatomi

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	9.1yrs
CEOの所有権	0.3%
経営陣の平均在職期間	6.1yrs
取締役会の平均在任期間	10.1yrs

経営陣の近況

Recent updates

Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥45.00

Jun 13

Why We're Not Concerned About Hisamitsu Pharmaceutical Co., Inc.'s (TSE:4530) Share Price

Apr 09

Here's Why We Think Hisamitsu Pharmaceutical (TSE:4530) Is Well Worth Watching

Mar 18

CEO（最高経営責任者

Kazuhide Nakatomi (52 yo)

9.1yrs

在職期間

Mr. Kazuhide Nakatomi serves as the President of Hisamitsu Pharmaceutical Co. Inc. since May 2015 and has been Chief Executive Officer since May 2019 and has been Director since May 2007 and served as its...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Kazuhide Nakatomi	President	9.1yrs	データなし	0.33% ¥ 890.8m
Nobuo Tsutsumi	GM of Legal Dept	10.1yrs	データなし	0.0068% ¥ 18.2m
Kazunori Ito	Executive Officer & GM of Human Resources Department	no data	データなし	データなし
Kyu Saito	MD, Executive Officer	no data	データなし	0.0095% ¥ 25.4m
Shinichi Murayama	Executive Officer of Mgmt. of Internal Audit Division & Domestic Subsidiary Division and Director	no data	データなし	0.0082% ¥ 21.8m
Mitsutoshi Tsuruta	Executive Officer & Head of Ethical Division	no data	データなし	データなし
Masaya Okuno	Executive Officer and Head of Sales & Marketing Division	no data	データなし	データなし
Koji Takiyama	Executive Officer	3.1yrs	データなし	0.0041% ¥ 10.9m
Katsuhiko Akiyama	Sr. Exe. Officer & GM of MN Commercialization Office	1.4yrs	データなし	データなし

6.1yrs

平均在職期間

57yo

平均年齢

経験豊富な経営陣: 4530の経営陣は経験豊富で経験豊富です（平均在職期間は6.1年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Kazuhide Nakatomi	President	17.1yrs	データなし	0.33% ¥ 890.8m
Nobuo Tsutsumi	GM of Legal Dept	10.1yrs	データなし	0.0068% ¥ 18.2m
Kyu Saito	MD, Executive Officer	11.1yrs	データなし	0.0095% ¥ 25.4m
Shinichi Murayama	Executive Officer of Mgmt. of Internal Audit Division & Domestic Subsidiary Division and Director	10.1yrs	データなし	0.0082% ¥ 21.8m
Koji Takiyama	Executive Officer	3.1yrs	データなし	0.0041% ¥ 10.9m
Munehiko Hirano	Standing Corporate Auditor	18.1yrs	データなし	0.0027% ¥ 7.3m
Nobuyuki Nakatomi	Standing Corporate Auditor	16.1yrs	データなし	0.34% ¥ 909.0m
Keinosuke Ono	Part-time Outside Corporate Auditor	no data	データなし	0.0027% ¥ 7.3m
Tetsugo Matsuo	Part-time Outside Independent Director	4.1yrs	データなし	0.0014% ¥ 3.6m
Teijiro Furukawa	Independent Outside Director	9.1yrs	データなし	データなし
Yuichiro Anzai	Part-time Outside Independent Director	4.1yrs	データなし	データなし
Tamako Watanabe	Part Time Outside Independent Director	1.1yrs	データなし	データなし

10.1yrs

平均在職期間

60.5yo

平均年齢

経験豊富なボード: 4530の取締役会は経験豊富で経験豊富です ( 10.1年の平均在任期間)。

Hisamitsu Pharmaceutical マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Hisamitsu Pharmaceutical Co., Inc., Annual General Meeting, May 23, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥45.00

Final dividend of JP¥45.00 announced

Hisamitsu Pharmaceutical Co., Inc. to Report Q1, 2025 Results on Jul 11, 2024

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) announces an Equity Buyback for 2,400,000 shares, representing 3.17% for ¥8,901.6 million.

Full year 2024 earnings: EPS misses analyst expectations

Hisamitsu Pharmaceutical Co., Inc., Annual General Meeting, May 23, 2024

Why We're Not Concerned About Hisamitsu Pharmaceutical Co., Inc.'s (TSE:4530) Share Price

Here's Why We Think Hisamitsu Pharmaceutical (TSE:4530) Is Well Worth Watching

Hisamitsu Pharmaceutical Co., Inc. to Report Fiscal Year 2024 Results on Apr 11, 2024

Upcoming dividend of JP¥42.50 per share

Price target decreased by 15% to JP¥4,250

Third quarter 2024 earnings released: EPS: JP¥48.25 (vs JP¥37.89 in 3Q 2023)

Hisamitsu Pharmaceutical Co., Inc. Announces Dividend for the Second Quarter and Provides Dividend Guidance for the Full Year Ending February 29, 2024

Hisamitsu Pharmaceutical Co., Inc. to Report Q3, 2024 Results on Jan 11, 2024

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of JP¥42.50 per share at 1.8% yield

Hisamitsu Pharmaceutical Co., Inc. to Report Q2, 2024 Results on Oct 06, 2023

Price target increased by 16% to JP¥4,450

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) announces an Equity Buyback for 2,000,000 shares, representing 2.57% for ¥10,000 million.

Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending February 29, 2024

Full year 2023 earnings: EPS misses analyst expectations

Hisamitsu Pharmaceutical Co., Inc. to Report Q1, 2024 Results on Jul 13, 2023

Full year 2023 earnings: EPS misses analyst expectations

Upcoming dividend of JP¥42.25 per share at 2.1% yield

Hisamitsu Pharmaceutical Co., Inc. to Report Fiscal Year 2023 Results on Apr 13, 2023

Third quarter 2023 earnings released: EPS: JP¥37.89 (vs JP¥14.91 in 3Q 2022)

Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending February 28, 2023

Price target increased to JP¥3,700

Less than half of directors are independent

Price target increased to JP¥3,700

Consensus forecasts updated

Hisamitsu Pharmaceutical Co., Inc. to Report Q3, 2023 Results on Jan 12, 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) announces an Equity Buyback for 2,000,000 shares, representing 2.51% for ¥10,000 million.

Hisamitsu Pharmaceutical Co., Inc. Announces Dividend for the Second Quarter Ended August 31, 2022, Payable on Nov. 9, 2022; Provides Dividend Guidance for the full year ending February 28, 2023

Hisamitsu Pharmaceutical Co., Inc. to Report Q2, 2023 Results on Oct 12, 2022

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Hisamitsu Pharmaceutical Co., Inc. Provides Dividend Guidance for the Second Quarter and Full Year Ending February 28, 2023

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Hisamitsu Pharmaceutical Co., Inc. to Report Q1, 2023 Results on Jul 07, 2022

Less than half of directors are independent

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Year Ending February 28, 2023

Upcoming dividend of JP¥42.00 per share

Upcoming dividend of JP¥42.00 per share

Hisamitsu Pharmaceutical Co., Inc. to Report Fiscal Year 2022 Results on Apr 07, 2022

Consensus EPS estimates fall by 19%

Price target decreased to JP¥3,600

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Year Ending February 28, 2022

Second quarter 2022 earnings released: EPS JP¥32.30 (vs JP¥43.82 in 2Q 2021)

Upcoming dividend of JP¥42.00 per share

First quarter 2022 earnings released: EPS JP¥28.90 (vs JP¥1.38 in 1Q 2021)

Full year 2021 earnings released: EPS JP¥113 (vs JP¥228 in FY 2020)

Hisamitsu Pharmaceutical Co., Inc. Provides Earnings Guidance for the Year Ending February 28, 2022

Upcoming Dividend of JP¥41.75 Per Share

Hisamitsu Pharmaceutical Co., Inc. to Report Fiscal Year 2021 Results on Apr 08, 2021

New 90-day high: JP¥6,430

Revenue and earnings miss expectations

Revenue and earnings miss expectations

Third quarter 2021 earnings released: EPS JP¥24.82

New 90-day high: JP¥6,370

New 90-day high: JP¥6,340

New 90-day high: JP¥6,230

Price target lowered to JP¥4,400

Hisamitsu Pharmaceutical Co., Inc. to Report Q3, 2021 Results on Jan 13, 2021

Hisamitsu Pharmaceutical Co., Inc. to Report Q2, 2021 Results on Oct 08, 2020

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

マネジメント基準チェック /24